Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
4(50%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
4
50%
Ph phase_3
3
38%

Phase Distribution

0

Early Stage

4

Mid Stage

3

Late Stage

Phase Distribution7 total trials
Phase 2Efficacy & side effects
4(57.1%)
Phase 3Large-scale testing
3(42.9%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

8

all time

Status Distribution
Active(5)
Completed(2)
Other(1)

Detailed Status

Recruiting2
Completed2
Active, not recruiting2
Not yet recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
4
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 24 (57.1%)
Phase 33 (42.9%)

Trials by Status

not_yet_recruiting113%
recruiting225%
unknown113%
completed225%
active_not_recruiting225%

Recent Activity

4 active trials
Showing 5 of 8
recruitingphase_3

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

NCT06239727
completedphase_2

Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma

NCT03984357
active_not_recruitingphase_3

PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma

NCT04907370
active_not_recruitingphase_2

Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma

NCT03930498
recruitingphase_3

PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients

NCT03907826
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT06239727Phase 3

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

Recruiting
NCT03984357Phase 2

Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma

Completed
NCT04907370Phase 3

PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma

Active Not Recruiting
NCT03930498Phase 2

Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma

Active Not Recruiting
NCT03907826Phase 3

PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients

Recruiting
NCT06195254

Stereotactic Body Radiotherapy Combined With PD-1 Blockers for Locally Advanced or Locally Recurrent Pancreatic Cancer

Completed
NCT05097781Phase 2

Local Radiotherapy in Combination With Immunotherapy in Advanced Solid Tumors Patients

Unknown
NCT04605562Phase 2

Umbrella Biomarker-Guided Therapy in NPC

Not Yet Recruiting

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8